Wednesday, November 25, 2009, 2:51am EST - Canadian Markets open in 6 hours and 39 minutes.
To create a watchlist or portfolio of shares, Sign-in or Register

Savient Pharmaceuticals, Inc. (SVNT)

On Nov 24: 13.25 USD  Down 0.09 (0.67%)  
MORE ON SVNT
Quotes
Charts
News & Info
Company
HereProfile
Analyst Coverage
Ownership
Financials
Profile Get Profile for:
Savient Pharmaceuticals, Inc.
One Tower Center
Fourteenth Floor
East Brunswick, NJ 08816
Phone: 732-418-9300
Fax: 732-418-0570
Web Site: http://www.savientpharma.com

DETAILS
Index Membership: S&P 600 SmallCap
S&P 1500 Super Comp
Sector: Healthcare
Industry: Biotechnology
Employees (last reported count): 73

BUSINESS SUMMARY
Savient Pharmaceuticals, Inc., a specialty biopharmaceutical company, focuses on developing, manufacturing, and marketing pharmaceutical products that target unmet medical needs. The company sells and distributes branded and generic versions of oxandrolone, a drug used to promote weight gain following involuntary weight loss. It distributes the branded version of oxandrolone in the United States, under the name Oxandrin and authorized generic version of oxandrolone through an agreement with Watson Pharma, Inc. The company also involves in developing KRYSTEXXA (pegloticase), a biologic PEGylated uricase enzyme to control hyperuricemia, and to manage signs and symptoms of gout, including the improvement of tophi, improvement in chronic pain, improved physical functioning, and decreased frequency of flares for patients with treatment-failure gout. It distributes its products through wholesalers. The company, formerly known as Bio-Technology General Corp., was founded in 1980 and is headquartered in East Brunswick, New Jersey.
Key Statistics

COMPANY WEBSITES
  • Home Page
  • Search Yahoo! for:
    More on Savient Pharmaceuticals, Inc.



    View Financials

    OFFICERS
      Pay Exercised
    Mr. Paul R. Hamelin R.Ph., 54
    Pres
    $ 344.00K $ 276.00K
    Mr. Philip K. Yachmetz J.D, 52
    Sr. VP, Sec. and Gen. Counsel
    $ 388.00K $ 520.00K
    Mr. David G. Gionco ,
    Chief Financial Officer, VP and Treasurer
    N/A N/A
    Mr. Peter Clarke Ph.D., 49
    VP of Manufacturing
    N/A N/A
    Dollar amounts are as of 31-Dec-08 and compensation values are for the last fiscal year ending on that date. "Pay" is salary, bonuses, etc. "Exercised" is the value of options exercised during the fiscal year.
    View Insiders


    Add to My Portfolio Add to Portfolio    Email to a Friend Email to a Friend
    Get Profile for Another Symbol:
    Symbol Lookup
    Latest News Canadian Indices